AVITA Medical Targets $92 Million–$94 Million In Sales As Cash Use Shrinks
RECELL sales led third-quarter growth, while another $10 million in borrowing helped ease management’s concerns about staying in business.
AVITA Medical, which sells treatments for burns, traumatic injuries and surgical wounds, raised its 2026 sales forecast to $92 million–$94 million from $86 million–$89 million Thursday, according to the earnings release accompanying its 8-K filing. Quarterly cash use fell to approximately $0.6 million, and management maintained its expectation of reaching cash flow breakeven in the fourth quarter.
RECELL Drives The Higher Forecast
Third-quarter revenue was approximately $26.1 million, up 53% from $17.1 million a year earlier and 20% from the second quarter. AVITA credited RECELL growth and greater adoption of Cohealyx for most of the increase.
RECELL produced $22.4 million in U.S. revenue, approximately 20% above the second quarter, as procedure volumes and account orders increased. Cohealyx sales reached $2.1 million, approximately 21% higher than the previous quarter, with more customers and additional hospital committee approvals.
RECELL is an FDA-approved device that allows clinicians to prepare a spray of a patient’s own skin cells where treatment takes place. AVITA also sells the collagen-based dermal matrix Cohealyx and the biosynthetic wound matrix PermeaDerm to U.S. burn, trauma and surgical centers, while using third-party distributors overseas.
PermeaDerm revenue was $0.6 million and international revenue was $0.9 million, both essentially unchanged from the second quarter. PermeaDerm study results reported in August met the main study goal: graft take and wound healing were comparable to allograft, with product costs 70% lower and preparation time reduced 95.7%.
The higher annual forecast represents approximately 28%–31% growth over 2025 revenue of $71.6 million. AVITA said the outlook implies fourth-quarter sales of $24.9 million–$26.9 million.
Margins Improve, Losses Narrow
Gross profit reached 84% of revenue, versus 81.3% a year earlier, helped by manufacturing efficiency and higher RECELL sales. RECELL’s own gross margin was 88.4%; AVITA expects that measure to stay between 86% and 90% over the coming quarters.
The other products carry different economics: AVITA receives 50% of Cohealyx’s average selling price and up to 55% for PermeaDerm, lowering the overall margin.
Operating expenses of $24.6 million were flat against the second quarter but up 7%, or $1.6 million, from a year earlier. Sales and marketing expenses rose $1.5 million, largely from commissions and pay; research and development expenses increased $1.0 million, mainly from pay, while general and administrative costs fell $0.9 million.
Net loss narrowed to $6.2 million, or $0.20 per share, from $13.2 million, or $0.46 per share, a year earlier. The latest loss included $2.1 million of non-cash expense from revaluing warrants as AVITA’s share price increased.
RCEL shares rose about 10% to $17.18 in Friday trading, as of 9:31 a.m. ET.
Borrowing Eases The Cash Squeeze
Net cash use fell from $3.2 million in the second quarter to approximately $0.6 million. AVITA finished the third quarter with approximately $10.5 million in cash, cash equivalents and marketable securities, compared with $11.1 million at its start.
Trailing twelve-month revenue of at least $85 million satisfied the condition for another $10 million draw from Perceptive Advisors. AVITA borrowed that money after quarter-end, bringing total facility borrowings to $60 million.
Improved operations and liquidity led management to conclude that substantial doubt about AVITA’s ability to keep operating had been alleviated. The company removed the going-concern qualification—its warning about remaining in business—from its quarterly report and classified the credit-facility debt as a long-term liability.
“on track to achieve cash flow breakeven in the fourth quarter.” —AVITA Medical’s Cary Vance.
National physician payment values and simpler billing codes for RECELL procedures will take effect January 1, 2027. The Centers for Medicare & Medicaid Services finalized those changes Wednesday, the company said.
Sources
- 8-K Filing — AVITA Medical, Inc. (RCEL) — SEC EDGAR
- Exhibit rcel-ex99_1.htm — AVITA Medical, Inc. 8-K exhibit — SEC EDGAR
- AVITA Medical Q3 2026 Earnings Call Transcript — benzinga.com
- AVITA Medical Announces National Medicare Physician Payment Framework and Simplified Billing Codes for RECELL Procedures in 2027 — Yahoo Finance
- AVITA Medical Reports Third Quarter Results — globenewswire.com
- AVITA Medical Announces National Medicare Physician Payment — globenewswire.com